Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

NCT03702894 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence

Interventions

DRUG: Clavamox
DRUG: Augmentin®

Sponsor

Pharmtechnology LLC

Collaborators

[object Object]